Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI

• Published in: Zhongliu fangzhi yanjiu Vol. 52; no. 6; pp. 429 - 435
• Main Authors: Zeng, Yiming, Fang, Wenfeng, Zhang, Li
• Format: Journal Article
• Language: Chinese; English
• Published: Tianjin China Anti-Cancer Association 2025; Magazine House of Cancer Research on Prevention and Treatment
• Subjects: Customization; egfr-mutant nsclc; egfr-tki resistance; Epidermal growth factor receptors; Immunotherapy; Kinases; Lung cancer; Mutants; Non-small cell lung carcinoma; novel drugs; Precision medicine; Quality of life; Small cell lung carcinoma; targeted therapy; Tyrosine; Tyrosine kinase inhibitors

EGFR-mutant non-small cell lung cancer (NSCLC) is a common type of lung cancer, with EGFR tyrosine kinase inhibitors (EGFR-TKIs) being the standard first-line treatment. However, most patients with NSCLC eventually develop resistance to EGFR-TKIs. Studies on the mechanism underlying EGFR-TKI resista...